Aberrant promoter CpG methylation and its translational applications in breast cancer  

作　　者：Ting-Xiu Xiang Ying Yuan Li-Li Li Zhao-Hui Wang Liang-Ying Dan Yan Chen Guo-Sheng Ren Qian Tao 

机构地区：[1]Molecular Oncology and Epigenetics Laboratory,The First Affiliated Hospital of Chongqing Medical University [2]Shenzhen Institutes of Advanced Technology,Chinese Academy of Sciences(CAS)-CUHK [3]Cancer Epigenetics Laboratory,Department of Clinical Oncology,Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences,The Chinese University of Hong Kong [4]Hong Kong and CUHK Shenzhen Research Institute

出　　处：《Chinese Journal of Cancer》2013年第1期12-20,共9页

基　　金：supported by grants from the National Natural Science Foundation of China(NSFC)(No.#81072148,#81071634and#30928012);Natural Science Foundation of Chongqing(No.2010BB5101);Shenzhen Science Fund for Distinguished Young Scholars(No.JC201005270328A)

摘　　要：Breast cancer is a complex disease driven by multiple factors including both genetic and epigenetic alterations.Recent studies revealed that abnormal gene expression induced by epigenetic changes,including aberrant promoter methylation and histone modification,plays a critical role in human breast carcinogenesis.Silencing of tumor suppressor genes(TSGs) by promoter CpG methylation facilitates cells growth and survival advantages and further results in tumor initiation and progression,thus directly contributing to breast tumorigenesis.Usually,aberrant promoter methylation of TSGs,which can be reversed by pharmacological reagents,occurs at the early stage of tumorigenesis and therefore may serve as a potential tumor marker for early diagnosis and therapeutic targeting of breast cancer.In this review,we summarize the epigenetic changes of multiple TSGs involved in breast pathogenesis and their potential clinical applications as tumor markers for early detection and treatment of breast cancer.Breast cancer is a complex disease driven by multiple factors including both genetic and epigenetic alterations. Recent studies revealed that abnormal gene expression induced by epigenetic changes, including aberrant promoter methylation and histone modification, plays a critical role in human breast carcinogenesis. Silencing of tumor suppressor genes （TSGs） by promoter CpG methyJation facilitates cells growth and survival advantages and further results in tumor initiation and progression, thus directly contributing to breast tumorigenesis. Usually, aberrant promoter methylation of TSGs, which can be reversed by pharmacological reagents, occurs at the early stage of tumorigenesis and therefore may serve as a potential tumor marker for early diagnosis and therapeutic targeting of breast cancer. In this review, we summarize the epigenetic changes of multiple TSGs involved in breast pathogenesis and their potential clinical applications as tumor markers for early detection and treatment of breast cancer.

关 键 词：临床应用 乳腺癌 甲基化 CPG 异常 子区 肿瘤抑制基因 肿瘤标志物 

分 类 号：R737.9[医药卫生—肿瘤]